Cellectis Gains FDA RMAT Designation for Lasme-cel in Pivotal Allogeneic CAR-T Program for r/r B-ALL

For CDMOs and outsourcing facilities building off-the-shelf cell therapy manufacturing capabilities, Cellectis's RMAT designation for lasmecabtagene timgedleucel (lasme-cel) signals an accelerating regulatory timeline that will shape capacity planning and process validation commitments in the near term.

The FDA granted the Regenerative Medicine Advanced Therapy designation on June 9, 2026, for lasme-cel, a CD22-targeting allogeneic CAR-T candidate indicated for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The designation was supported by Phase 1 BALLI-01 trial data showing efficacy and a manageable safety profile. RMAT status enables more frequent FDA interactions, rolling review eligibility, and the potential for accelerated approval, each of which compresses the window between pivotal data readout and a Biologics License Application submission.

The manufacturing read is direct: allogeneic CAR-T platforms require batch-release strategies, donor-derived starting material controls, and sterility assurance frameworks that differ materially from autologous approaches. As lasme-cel advances through its pivotal Phase 2, currently open for enrollment under NCT04150497, manufacturers supporting the program will need process validation packages aligned with 21 CFR Part 211 and ICH Q10 quality system expectations, with the added complexity of gene-edited allogeneic cell products under heightened FDA scrutiny.

Cellectis describes lasme-cel as the first allogeneic CAR-T therapy in a pivotal trial for this indication, a positioning that places it ahead of competing off-the-shelf programs in the regulatory queue. Final Phase 1 BALLI-01 data are scheduled for oral presentation at the 2026 European Hematology Association Congress on June 13, delivered by Nitin Jain, M.D., of MD Anderson Cancer Center, a data package that will inform the evidentiary baseline regulators carry into pivotal review discussions.

The pace at which Cellectis converts RMAT engagement into a BLA submission will serve as a practical benchmark for the broader allogeneic cell therapy sector's regulatory readiness.

Source: Cellectis press release via cellectis.com, June 9, 2026.